Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.

IF 2 Q3 ONCOLOGY
William C Reinhold, Elisabetta Marangoni, Fathi Elloumi, Remi Montagne, Sudhir Varma, Yanghsin Wang, Keyvan Rezai, Ludivine Morriset, Ahmed Dahmani, Rania El Botty, Léa Huguet, Makito Mizunuma, Naoko Takebe, Samuel Huguet, Augustin Luna, Yves Pommier
{"title":"Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.","authors":"William C Reinhold, Elisabetta Marangoni, Fathi Elloumi, Remi Montagne, Sudhir Varma, Yanghsin Wang, Keyvan Rezai, Ludivine Morriset, Ahmed Dahmani, Rania El Botty, Léa Huguet, Makito Mizunuma, Naoko Takebe, Samuel Huguet, Augustin Luna, Yves Pommier","doi":"10.1158/2767-9764.CRC-24-0435","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy adding other genes in multivariate analysis for triple negative breast cancer (TNBC). Acetalax has a biphasic mean half-life of 5.8 hours.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"375-388"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869203/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy adding other genes in multivariate analysis for triple negative breast cancer (TNBC). Acetalax has a biphasic mean half-life of 5.8 hours.

求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信